Related Experiment Video
Updated: Jul 25, 2026
10:17
The Tail Suspension Test
Published on: January 28, 2012
Lithium isotopes: differential effects on renal function and histology.
P M Stoll1, P E Stokes, M Okamoto
1Department of Psychiatry, Weill Medical College of Cornell University, New York, NY, USA. peter.stoll@roche.com
Bipolar Disorders
|September 13, 2001
Summary
The stable lithium isotope 6Li causes greater kidney damage and reduced concentrating ability than 7Li in rats. Reducing 6Li in lithium treatments may decrease nephrotoxicity.
Area of Science:
- Nephrology
- Pharmacology
- Toxicology
Background:
- Chronic lithium treatment can impair renal concentrating ability.
- Stable lithium isotopes, 6Li and 7Li, exhibit different physiological effects.
- Understanding isotope-specific nephrotoxicity is crucial for optimizing lithium therapy.
Purpose of the Study:
- To compare the effects of 6LiCl, 7LiCl, and a mixed isotope preparation on rat kidney function and histology.
- To quantify polyuria, polydipsia, and renal histological changes induced by different lithium isotopes.
- To investigate the potential for isotope-selective nephrotoxicity in lithium treatment.
Main Methods:
- Rats received equimolar subcutaneous injections of 6LiCl, 7LiCl, or a mixed isotope preparation ('nLiCl') twice daily for up to 49 days.
- Daily measurements of 24-hour urine volume and water intake were recorded.
- Kidney histology was assessed after 7 days of treatment, with lesions graded for severity.
Main Results:
- All lithium-treated rats exhibited reduced renal concentrating ability, evidenced by increased urine volume and water intake.
- The peak effects of polyuria and polydipsia were significantly greater with 6LiCl compared to 7LiCl.
- Chronic administration of 6LiCl led to more severe renal tubular lesions than 7LiCl.
Conclusions:
- The lithium isotope 6Li demonstrates greater nephrotoxic potential than 7Li in rats.
- Reducing or eliminating 6Li from pharmaceutical lithium preparations warrants further investigation.
- Isotope-specific modifications may offer a strategy for developing less nephrotoxic lithium therapies.
Related Concept Videos
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Serum Studies: Renal Function Tests
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.